AEON AMEX
AEON Biopharma, Inc.
1W: -0.1%
1M: -2.8%
3M: -63.9%
YTD: -76.3%
1Y: -67.1%
3Y: -99.9%
$0.28
-0.01 (-3.79%)
Weekly Expected Move ±19.7%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (22)
AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference
HC Wainwright Comments on AEON Biopharma Q3 Earnings
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
AEON Biopharma regains NYSE American listing compliance after $13.6M offering
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
12 Health Care Stocks Moving In Monday's Intraday Session
AEON Biopharma Sets Annual Shareholder Meeting
AEON Biopharma receives additional NYSE American non-compliance notice
AEON Biopharma GAAP EPS of -$3.95
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
AEON Biopharma (NASDAQ:AEON) Trading 1.8% Higher – Here’s Why
AEON Biopharma appoints John Bencich as CFO
AEON Biopharma Appoints John Bencich as Chief Financial Officer
AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting
AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
AEON Biopharma Announces Execution of Exchange Agreement with Daewoong
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling